-
The authors performed a prospective cohort study, the contraceptive CHOICE Project, in which women in the St. Louis, Missouri, region received a reversible contraceptive method of their choice for up to 3 years at no cost.
-
Apropos of the recent emphasis on discouraging elective deliveries prior to 39 weeks, a group from Cincinnati embarked on a study to determine whether steroids had any neonatal benefit in patients delivering between 34 and 39 weeks who had immature amniotic fluid lung profiles.
-
In this issue: Lorcaserin for weight loss; statins and fatigue; treatment-resistant gonorrhea; hydrocodone classification changes; USPSTF recommendations; and FDA actions.
-
Researchers from duke university and the university of California, San Francisco enrolled 40 patients with symptoms of overactive bladder (OAB), i.e., urgency, frequency, and/or urge incontinence, and 40 patients with no history of OAB symptoms. The women's view of symptoms and treatments were measured with a utility score.
-
-
Poly(adenosine diphosphate [adp]-ribose) polymerase (PARP) is an enzyme participating in low-fidelity DNA repair of single strand breaks. Pharmacologic inhibition of PARP has shown to be effective in tumors lacking homologous recombination, such as those harboring silencing mutations of BRCA1 and 2.
-
To provide guidance to clinicians on the use of hormone replacement therapy, the authors conducted a systematic review of the randomized, placebo-controlled trials of menopausal hormone therapy published in English since 2002 that assessed primary prevention of chronic conditions.
-
The World Health Organization (WHO) has reaffirmed its guidance that women living with HIV or at high risk of HIV infection can safely use all hormonal contraceptives without restriction following a recent review of links between the contraceptives and HIV acquisition.
-
Reaching young people with an HIV prevention message is important: The Centers for Disease Control and Prevention (CDC) estimates young people ages 13-29 accounted for 39% of all new HIV infections in 2009.
-
With relatively few contraindications to use, progestin-only pills might be a possible candidate for over-the-counter (OTC) use in the United States. But what will it take to move progestin-only pills to the drugstore shelves?
